Company Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 11:18:34 17/07/2024 pm IST			5-day change	1st Jan Change
3.515 ^USD	+19.15%		-7.74%	+4.93%

07/05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05/03	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Companyâs portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Number of employees: 1

Managers	Title	Age	Since
Regina Graul PSD	President	47	04/12
Peter Hecht BRD	Director/Board Member	60	01/19/01

Members of the board	Title	Age	Since
Errol de Souza CHM	Chairman	70	26/21/26
Peter Hecht BRD	Director/Board Member	60	01/19/01
Steven Hyman BRD	Director/Board Member	71	25/22/25
Michael Higgins BRD	Director/Board Member	61	30/11
Dina Katabi BRD	Director/Board Member	52	30/11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,920,591	2,116,493 ( 72.47 %)	210,495 ( 7.207 %)	72.47 %
Stock B	0	351,037	0	0

Name	Equities	%	Valuation
Peter Hecht 13.93 %	377,385	13.93 %	867 986 $
Slate Path Capital LP 13.21 %	357,880	13.21 %	823 124 $
MFN Partners Management LP 6.253 %	169,460	6.253 %	389 758 $
Tyndall Management LLC 6.080 %	164,777	6.080 %	378 987 $
Fidelity Management & Research Co. LLC 5.990 %	162,327	5.990 %	373 352 $
Artal Group SA 5.127 %	138,955	5.127 %	319 597 $
Invus Public Equities Advisors LLC 4.266 %	115,603	4.266 %	265 887 $
Regina Graul 3.701 %	100,303	3.701 %	230 697 $
Errol de Souza 1.845 %	50,000	1.845 %	115 000 $
Terry McGuire 1.550 %	42,018	1.550 %	96 641 $

Name	Equities	%	Valuation
Peter Hecht 100.00 %	351,037	100.00 %	807 385 $

Cyclerion Therapeutics, Inc.

Riverview II 245 First Street

02142, Cambridge

http://www.cyclerion.com

address Cyclerion Therapeutics, Inc.(CYCN)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CYCLERION THERAPEUTICS, INC.	+4.93%	73.74L
MODERNA, INC.	+23.88%	4.8TCr
IQVIA HOLDINGS INC.	+0.36%	4.24TCr
LONZA GROUP AG	+43.96%	4.15TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.87%	3.16TCr
ICON PUBLIC LIMITED COMPANY	+20.62%	2.86TCr
CELLTRION, INC.	-4.47%	2.8TCr
UNITED THERAPEUTICS CORPORATION	+51.64%	1.46TCr
MEDPACE HOLDINGS, INC.	+44.49%	1.41TCr
BIO-TECHNE CORPORATION	+1.93%	1.26TCr

Other Biotechnology & Medical Research